Century Therapeutics CEO Brent Pfeiffenberger forfeited 463 shares at $2.11 per share on September 4, 2026, leaving him with 3,633,839 shares. The transaction represented about 0.0% of his prior holding, making the reported change small relative to his remaining ownership position.
Key Highlights
- The transaction took place on September 4, 2026.
- The filing used transaction code F, which denotes tax-related share withholding.
- Pfeiffenberger’s forfeiture represented about 0.0% of his prior share holding.
Century Therapeutics, Inc. (NASDAQ: IPSC) CEO Brent Pfeiffenberger forfeited 463 shares at $2.11 per share, leaving him with 3,633,839 shares. The transaction represented about 0.0% of his prior holding.
September 4 Share Forfeiture
The transaction occurred on September 4, 2026. Century Therapeutics identified Pfeiffenberger as its president and chief executive officer. The per-share value was $2.11. Pfeiffenberger’s resulting ownership stood at 3,633,839 shares after the transaction.
Limited Change to Reported Ownership
The forfeiture equaled about 0.0% of Pfeiffenberger’s prior share holding. Century Therapeutics provided the ownership figure alongside the transaction details. The reported balance remains 3,633,839 shares. The disclosed percentage was about 0.0%.
FAQs
Q: How many Century Therapeutics shares did Brent Pfeiffenberger forfeit?
A: Brent Pfeiffenberger forfeited 463 Century Therapeutics shares at $2.11 per share. He remained the holder of 3,633,839 shares after the transaction.
Q: What was the impact of the Century Therapeutics CEO share transaction?
A: The forfeiture represented about 0.0% of Brent Pfeiffenberger’s prior share holding. His reported ownership after the transaction was 3,633,839 shares.
Q: When did the Century Therapeutics share forfeiture occur?
A: The Century Therapeutics share forfeiture occurred on September 4, 2026. The transaction involved President and CEO Brent Pfeiffenberger and carried transaction code F.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.